“
A long-term injection given 6 times a year or once every 2 months is an alternative to daily pills to protect against the virus, reports BBC.
Experts hope that injectable cabotegravir (CAB-LA) will help Britain meet its ambitious goal of ending new HIV infections by 2030.
“The approval of this revolutionary injection is a great example of what our government is committed to – innovative treatments that save lives and leave no one behind.
For vulnerable people who cannot use other methods of HIV prevention, this gives hope”said Secretary of State for Health and Social Care Wes Streeting.
HIV prevention therapy, known as PrEP (pre-exposure prophylaxis), is for people who do not yet have HIV. The pills have been available for many years and remain extremely effective in preventing HIV infection, but not everyone is comfortable using these medications. Sometimes patients find it difficult, inconvenient, or embarrassing to receive them.
Homelessness and domestic violence also make it difficult to take PrEP every day. Instead, the injection, which lasts for several months, can help a person maintain privacy and not show everyone that they are on prevention.
Cabotegravir, made by ViiV Healthcare, will be able to be recommended for adults and adolescents of normal weight who are at high risk of sexually transmitted HIV infection and are eligible for PrEP but cannot take the pill.
About a thousand people are expected to receive the injection. Many other patients will stay on the pills or start taking them.
People will be able to get the injections at NHS sexual health clinics in the coming months.
As a reminder, injectable HIV prevention (cabotegravir CAB-LA) has already been approved in more than 50 countries, including Great Britain, Canada, Australia, Brazil, South Africa, Zimbabwe, Zambia, Malaysia and EU countries. They approved it as a long-term alternative to daily PrEP pills. Innovative drug for the first time in Ukraine received two patients in 2024.
”, — write: www.pravda.com.ua
A long-term injection given 6 times a year or once every 2 months is an alternative to daily pills to protect against the virus, reports BBC.
Experts hope that injectable cabotegravir (CAB-LA) will help Britain meet its ambitious goal of ending new HIV infections by 2030.
“The approval of this revolutionary injection is a great example of what our government is committed to – innovative treatments that save lives and leave no one behind.
For vulnerable people who cannot use other methods of HIV prevention, this gives hope”said Secretary of State for Health and Social Care Wes Streeting.
HIV prevention therapy, known as PrEP (pre-exposure prophylaxis), is for people who do not yet have HIV. The pills have been available for many years and remain extremely effective in preventing HIV infection, but not everyone is comfortable using these medications. Sometimes patients find it difficult, inconvenient, or embarrassing to receive them.
Homelessness and domestic violence also make it difficult to take PrEP every day. Instead, the injection, which lasts for several months, can help a person maintain privacy and not show everyone that they are on prevention.
Cabotegravir, made by ViiV Healthcare, will be able to be recommended for adults and adolescents of normal weight who are at high risk of sexually transmitted HIV infection and are eligible for PrEP but cannot take the pill.
About a thousand people are expected to receive the injection. Many other patients will stay on the pills or start taking them.
People will be able to get the injections at NHS sexual health clinics in the coming months.
As a reminder, injectable HIV prevention (cabotegravir CAB-LA) has already been approved in more than 50 countries, including Great Britain, Canada, Australia, Brazil, South Africa, Zimbabwe, Zambia, Malaysia and EU countries. They approved it as a long-term alternative to daily PrEP pills. Innovative drug for the first time in Ukraine received two patients in 2024.